Last reviewed · How we verify
NCT06942143
An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors
Phase 1 trial testing Super1 TCR-T in Sarcoma in 15 participants. Currently enrolling.
25 April 2027
Quick facts
| Lead sponsor | Guangzhou FineImmune Biotechnology Co., LTD. |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 22 May 2025 |
| Primary completion | 25 April 2027 |
| Estimated completion | 25 June 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Super1 TCR-T — full drug profile →
Conditions studied
- Sarcoma — all drugs for Sarcoma →
- Lung Cancers — all drugs for Lung Cancers →
- Melanoma — all drugs for Melanoma →
Sponsor
Guangzhou FineImmune Biotechnology Co., LTD. — full company profile →
Who can join
Adults 18 to 75, any sex, with Sarcoma or Lung Cancers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study was a phase I safety and tolerability clinical trial conducted in a single-center, open-label, 3+3 design with dose escalation.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
After a Decade of Therapy Revolution in Cutaneous Melanoma-Perspectives on Emerging Treatment Strategies.
Wohlfeil SA, Utikal JS. · · 2026 · PMID 42232604 · DOI 10.32604/or.2026.078650 -
Immune Exhaustion in Chronic Infection and Cancer: Signaling Pathways and Therapeutic Interventions.
Song Y, Mo Y, Chen S, Chen Y, et al · · 2026 · PMID 41768369 · DOI 10.1002/mco2.70635 -
Immunotherapy for high-grade endometrial stromal sarcoma: a narrative review bridging molecular insights to clinical translation.
Zhao L, Su Y, Li X, Wang F, et al · · 2025 · PMID 40977714 · DOI 10.3389/fimmu.2025.1645371
Verify or expand the search:
- PubMed search for NCT06942143
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sarcoma
Currently open trials in the same condition.
- NCT07402577 — Brief Title Mechanisms of Cancer-Related Pain and Opioid Use Among Adolescents and Young Adult Sarcoma Survivors: Pilot · recruiting
- NCT07501026 — Preoperative Spatially Fractionated Radiation Therapy (SFRT) in Soft Tissue Sarcoma (neoSFRT-SARC) · Phase 2 · recruiting
- NCT07359911 — Effect of A Multimodal Exercise Intervention on Chemotherapy Uptake in Newly Diagnosed Pediatric and AYA Sarcoma Patient · NA · recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07222735 — Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcoma · Phase 1 · recruiting
Other Guangzhou FineImmune Biotechnology Co., LTD. trials
Trials by the same sponsor.
- NCT07493044 — An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma · Phase 1 · recruiting
- NCT06716619 — A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors · Phase 1 · recruiting
- NCT06302062 — Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors · Phase 1 · recruiting
- NCT03891706 — Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06942143 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangzhou FineImmune Biotechnology Co., LTD.
- Last refreshed: 3 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06942143.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing